Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
Authors:
Preprint
- 11 March 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
PurposeAutoantibodies (aAbs) to type I interferons (IFNs) have been found in MethodsELISA and ISRE reporter assays were used to detect aAbs and naAbs using E. coli-produced IFNs.ResultsIn an uninfected general Japanese population aged 20–91, we found aAbs in 0.087% of individuals. naAbs to type I IFNs (IFN-α2 and/or IFN-ω, 100 pg/mL) were detected in 10.6% of patients with critical infections, 2.6% of patients with severe infections, and ≤1% of patients with asymptomatic to mild infections. They were higher in COVID-19 patients over 50 (5.8%) than in younger patients (0%) and higher in men (5.5%) than in women (1.1%). A significant but not strong correlation between aAbs and naAbs to IFN-α2 existed (r=-0.307, p-valueConclusionIn the largest study focusing on a single ethnic and geographic group, we show that Japanese individuals with pre-existing naAbs have a much higher risk of life-threatening COVID-19 pneumonia.Keywords
All Related Versions
This publication has 31 references indexed in Scilit:
- Interferon β-1b in treatment of severe COVID-19: A randomized clinical trialInternational Immunopharmacology, 2020
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19Science, 2020
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsScience, 2020
- Type I IFN immunoprofiling in COVID-19 patientsJournal of Allergy and Clinical Immunology, 2020
- Clinical and pathological investigation of patients with severe COVID-19JCI Insight, 2020
- A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 InfectionCell, 2020
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialThe Lancet, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020